Combination therapy with anti-PD-1 antibody, radiotherapy, and tyrosine kinase inhibitor for unresectable primary ectopic hepatocellular carcinoma: a case report with genomic profiling and literature review - Scorecard - MDSpire
Advertisement
Combination therapy with anti-PD-1 antibody, radiotherapy, and tyrosine kinase inhibitor for unresectable primary ectopic hepatocellular carcinoma: a case report with genomic profiling and literature review
Clinical Scorecard: Multimodal Treatment Approach for Unresectable Primary Ectopic Hepatocellular Carcinoma: A Case Study with Genomic Analysis and Review of Existing Literature
At a Glance
Category
Detail
Condition
Ectopic Hepatocellular Carcinoma (EHCC)
Key Mechanisms
Involvement of the interferon response pathway in EHCC pathogenesis.
Target Population
Patients with unresectable EHCC.
Care Setting
Multidisciplinary team (MDT) management in a clinical setting.
Key Highlights
EHCC is a rare malignancy occurring outside the liver without a detectable intrahepatic primary tumor.
The patient achieved a progression-free survival (PFS) of 27 months and an overall survival (OS) of 30 months.
Combination therapy included lenvatinib, camrelizumab, and stereotactic body radiotherapy (SBRT).
Comprehensive genomic profiling revealed significant molecular features relevant to EHCC.
No standardized management guidelines currently exist for EHCC.
Guideline-Based Recommendations
Diagnosis
Diagnosis confirmed by laparoscopic biopsy and histopathological examination.
Management
Multimodal treatment approach involving MDT for individualized care.
Monitoring & Follow-up
Regular assessment of progression-free survival and overall survival.
Risks
Poor prognosis for patients with unresectable EHCC characterized by multiple disseminated lesions.
Patient & Prescribing Data
A patient in his sixties with unresectable, multifocal EHCC.
Combination therapy with lenvatinib, camrelizumab, and SBRT showed favorable outcomes.
Clinical Best Practices
Utilize comprehensive genomic profiling to inform treatment strategies.
Implement MDT-based care for complex cases of EHCC.
